Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC reduced its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 10.2% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,480,284 shares of the company's stock after selling 508,463 shares during the quarter. Janus Henderson Group PLC owned 9.33% of Mirum Pharmaceuticals worth $174,738,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Quest Partners LLC increased its position in shares of Mirum Pharmaceuticals by 7,513.3% during the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company's stock valued at $39,000 after purchasing an additional 1,127 shares during the last quarter. Amalgamated Bank increased its position in shares of Mirum Pharmaceuticals by 60.8% during the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company's stock valued at $46,000 after purchasing an additional 513 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock valued at $67,000 after purchasing an additional 318 shares during the last quarter. ProShare Advisors LLC bought a new position in Mirum Pharmaceuticals during the 2nd quarter worth approximately $213,000. Finally, Creative Planning bought a new position in Mirum Pharmaceuticals during the 3rd quarter worth approximately $249,000.

Mirum Pharmaceuticals Trading Down 0.3 %

Shares of MIRM traded down $0.12 during mid-day trading on Wednesday, reaching $45.47. The stock had a trading volume of 219,494 shares, compared to its average volume of 548,944. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -22.51 and a beta of 1.20. The business's fifty day moving average is $41.34 and its 200 day moving average is $37.84. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million for the quarter, compared to analysts' expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm's revenue was up 89.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.57) earnings per share. On average, sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Analysts Set New Price Targets

MIRM has been the subject of several research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Leerink Partners raised their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an "outperform" rating in a research report on Thursday, October 17th. Citigroup raised their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Cantor Fitzgerald upped their price objective on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday, August 8th. Finally, Evercore ISI lifted their target price on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an "outperform" rating in a report on Thursday, August 8th. Ten equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Mirum Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $57.73.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,500 shares of the company's stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $47.10, for a total value of $117,750.00. Following the transaction, the senior vice president now directly owns 2,426 shares of the company's stock, valued at $114,264.60. This represents a 50.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 22.87% of the stock is owned by corporate insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.